Incyte comes of age with JAK inhibitor approval.
Nuala
N
Moran
D001549:Benzamides / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors*; D053614:Janus Kinase 2 / Q000037:antagonists & inhibitors*; D009570:Nitriles; D055728:Primary Myelofibrosis / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D001549:Benzamides; D009570:Nitriles; D011720:Pyrazoles; D011743:Pyrimidines; C546012:N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; C540383:ruxolitinib; C507904:JAK1 protein, human; C507924:JAK2 protein, human; D053613:Janus Kinase 1; D053614:Janus Kinase 2